MapLight Therapeutics Secures $225M in Series C as Brain Monitoring Market Grows
MapLight Therapeutics, a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, recently announced the successful closure of a $225 million Series C financing round. This significant funding will advance their diverse pipeline of novel therapeutics, including ML-007C-MA for schizophrenia and Alzheimer’s disease psychosis, ML-007 for dyskinesia, and ML-004 for autism spectrum disorder. The investment attracted notable backers such as Novo Holdings, 5AM Ventures, and Cowen Healthcare Investments, reflecting confidence in MapLight’s innovative approach and potential market impact.
Novo Holdings, a major investor, is a private limited liability company owned by the Novo Nordisk Foundation, with a strong portfolio in life sciences. 5AM Ventures, known for building next-generation life science companies, and Cowen Healthcare Investments, a part of Cowen Inc., are prominent in healthcare therapeutics and technology investments. Their involvement underscores the potential of MapLight’s pipeline in addressing unmet needs in CNS disorders.
The financing aligns with the expanding global brain monitoring market, estimated to grow from $5.8 billion in 2021 to $8.0 billion by 2026, at a CAGR of 6.5%. This growth is propelled by the increasing incidence of neurological disorders, heightened awareness of neurodegenerative diseases, and the demand for non-invasive and minimally invasive brain monitoring devices. The devices segment holds a substantial market share, catering to conditions like traumatic brain injury, which requires intensive brain monitoring.
MapLight’s innovative therapies address critical gaps in treating challenging CNS conditions. ML-007C-MA, a novel muscarinic agonist agent, targets schizophrenia and Alzheimer’s psychosis, conditions with significant unmet medical needs. ML-004, a 5HT-1b agonist, aims to treat social communication deficits in autism spectrum disorder, a field with limited therapeutic options.
North America, leading the brain monitoring market with a 38% share, offers a promising landscape for MapLight’s growth. The region's strong clinical trial network, medical reimbursement policies, and rising neurological disease incidence create a conducive environment for new CNS treatments.
MapLight’s strategic focus on circuit-based discovery and development of targeted therapeutics stands at the intersection of significant market need and scientific innovation. This funding round not only bolsters their position in the CNS therapeutic landscape but also signifies the increasing investor confidence in novel approaches to tackling complex brain disorders.
Letter to EditorGET AHEAD
Top Research Reports to Fuel Your Industry KnowledgeEditor's Pick
Information and Communication Technology
Insurtech Funding News - Coverdash raises USD 13.5 Million
PODCASTS
Sustainable Digital Transformation & Industry 4.0
Sanjay Kaul, President-Asia Pacific & Japan, Cisco, and host Aashish Mehra, Chief Research Officer, MarketsandMarkets, in conversation on unraveling 'Sustainable Digital Transformation and Industry 4.0'
11 July 2023|S2E12|Listen Now
Generative AI
Prasad Joshi, Senior Vice President-Emerging Technology Solutions, Infosys, and host, Vinod Chikkareddy, CCO, MarketsandMarkets, in exploring the recent advances in AI and the generative AI space.
7 Nov 2023|S2E13|Listen Now
Brain Monitoring Market
Download Whitepaper
North America, leading the brain monitoring market with a 38% share, offers a promising landscape for MapLight’s growth.
MapLight’s innovative therapies address critical gaps in treating challenging CNS conditions. ML-007C-MA, a novel muscarinic agonist agent, targets schizophrenia and Alzheimer’s psychosis, conditions with significant unmet medical needs.
Follow IndustryNews by MarketsandMarkets
